Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential

HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20–30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Immunotherapy
Main Authors: De La Cruz, Lucy M, Nocera, Nadia F, Czerniecki, Brian J
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2016
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5967360/
https://ncbi.nlm.nih.gov/pubmed/27605070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2016-0052
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados